U.S. Panel Partially Backs Merck Anti-Nausea Drug
The advisory panel unanimously said Emend, the first in a new class of drugs, was effective for helping to prevent those distressing side effects for up to five days after chemotherapy.
A majority said the drug appeared safe for use with regimens containing any of three commonly used chemotherapy agents and another drug called Cisplatin.
But the panel ruled Merck did not study enough patients to rule out chances of dangerous interactions with six other chemotherapy agents. Merck's study contained few or no patients treated with those drugs, the Food and Drug Administration said.
The FDA, which is considering Emend under a faster-than-usual priority review, usually follows its panels' advice.
"We're very pleased with the decision of the committee. We believe the committee did see Emend as a true medical advance for patients," Merck spokesman Chris Loder said.
Patients dread post-chemo nausea and vomiting so much that some may even delay treatment, Merck officials said.
The company touted Emend's ability to prevent nausea and vomiting for up to five days. Other therapies do not work well for that long, said Dr. Steven Grunberg, a University of Vermont professor of medicine and pharmacology and a Merck consultant.
Emend "is the first one with a major effect" in the two to five days following treatment, Grunberg said in an interview.
Emend works differently than other drugs currently given to prevent the chemotherapy side effects. Emend blocks substance P, one of the body's chemical messengers that sends a signal to the brain for nausea and vomiting.
One Merck study showed 73 percent of patients treated with Emend and two other drugs had no vomiting in the five days after treatment started and no need to take medicines to control nausea. Only 52 percent of patients given the standard anti-vomiting drugs alone achieved that result.
The other anti-vomiting drugs were Glaxosmithkline PLC's Zofran and a corticosteroid called dexamethasone.
FDA officials voiced concern that Emend, known generically as aprepitant, might interact with certain chemotherapy drugs and cause serious, life-threatening toxicity. Panel members said they were persuaded of Emend's safety with regimens containing three commonly used drugs -- Paclitaxel, Etoposide and Vinorelbine.
Merck tested those drugs most extensively because they are among the most commonly used, Grunberg said.
Many panelists urged post-marketing studies of the six other chemotherapy agents to look for any interactions.
Some analysts expect Emend to have annual sales of roughly $400 million in 2006. That would make it a medium-sized drug for Merck, which has annual pharmaceutical sales of about $25 billion, but badly needs new drugs to replace medicines that have lost patent protection in recent years.
Ira Loss, an analyst with Washington Analysis, said he expected Emend would be approved and oncologists would use it with drugs other than just those in the chemotherapy regimens the committee supported.
"I tend to think oncologists, if patients are having a great deal of trouble with (vomiting), will use this drug," loss said. Merck shares rose 8 cents to close at $51.95. (Reuters)